SEHK:2591Biotechs
Guangzhou Innogen Pharmaceutical Group (SEHK:2591) Heavy Losses Challenge High Growth Narratives
Guangzhou Innogen Pharmaceutical Group (SEHK:2591) has reported its FY 2025 first half with revenue of C¥56.4 million, a basic EPS loss of C¥0.29 and net income loss of C¥122.47 million, while trailing twelve month figures show revenue of C¥131.5 million, a basic EPS loss of C¥0.79 and net income loss of C¥341.36 million. The company has seen first half revenue move from C¥0 in FY 2024 to C¥56.4 million in FY 2025 as EPS moved from a basic loss of C¥0.18 to a loss of C¥0.29. This sets up a...